11/12 October 2022
As a part of new or revised guidance documents on clinical trial design, the FDA published the revised draft guidance on "Adaptive Designs for Clinical Trials of Drugs and Biologics". This document will replace the 2010 draft guidance for industry "Adaptive Design Clinical Trials for Drugs and Biologics". It is supposed to support sponsors of investigational new drug applications (INDs), new drug applications (NDAs), biologics licensing applications (BLAs), or supplemental applications.
The document's aim is to provide recommendations on the appropriate use of adaptive designs for clinical trials in order to provide evidence of the effectiveness and safety of a drug or biologic. Adaptive Designs are defined "as a clinical trial design that allows for prospectively planned modifications to one or more aspects of the design based on accumulating data from subjects in the trial."
The revised document includes important principles for designing, conducting, and reporting the results of an adaptive clinical trial and provides details about the information needed by the authorities in order to evaluate the results of clinical trials with adaptive designs. The main focus is on adaptive designs for clinical trials intended to support the effectiveness and safety of drugs. Therefore, the guidance covers the following bullets:
For more details please read the complete revised guideline on Adaptive Designs for Clinical Trials of Drugs and Biologics.